Crinetics reports Q3 EPS ($1.38), consensus ($1.25)

Reports Q3 revenue $143,00, consensus $394,000. “September 25, 2025 was a historic day for Crinetics (CRNX) with the approval of Palsonify for the treatment of people with acromegaly,” said Scott Struthers, Founder and Chief Executive Officer of Crinetics. “For years, acromegaly patients have endured significant challenges with existing therapies. Since approval, our team has executed seamlessly to get Palsonify to patients and the launch is off to a very good start. Healthcare providers both at pituitary centers and in the community have written prescriptions, and we are seeing uptake in patients switching from prior therapies and in those newly initiating medical therapy. With the approval milestone, we are now a fully integrated pharmaceutical company. Five clinical trials across our deep pipeline are advancing and our financial position remains robust. We are executing with speed and focus on our mission to bring life-changing treatments to the patients who need them most.”